Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted ...
manilatimes1d
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The company granted stock options to purchase an aggregate of 208,350 shares of Nurix common stock and restricted stock unit ...
Leveraging a novel protein tagging strategy offers new route to cancer treatment
In a pioneering collaboration with AbbVie, Northwestern researchers have discovered a new way to potentially treat cancer by ...
News Medical3d
Study identifies vitamin E succinate as key to tumor growth control
High levels of fat mass and obesity-associated protein (FTO) have been linked to increased tumor growth and resistance to ...
BioWorld3d
Merck Sharp & Dohme prepares new KRAS G12D degrader PROTACs
Merck Sharp & Dohme LLC patents report the development of proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase (Von Hippel-Lindau disease tumor suppressor [VHL] ligands) ...
Vitamin E succinate shown to control tumor growth and enhance immunotherapy effects
High levels of fat mass and obesity-associated protein (FTO) have been linked to increased tumor growth and resistance to ...